Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .

Clinical trial NCT06734533 · RECRUITING

Trial details

NCT number: NCT06734533
Sponsor: Hunan Cancer Hospital
Status: RECRUITING
Study type: OBSERVATIONAL

HR+ Breast Cancer

Start date: 2024-12-05
Primary completion: 2025-12-01
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.